Annual Report to the Nation on the Status of Cancer, 1975-2014, Featuring Survival

Journal of the National Cancer Institute

Volumn 109, Issue 9, 2017, Pages

  Jemal, Ahmedin ^a   Ward, Elizabeth M ^a   Johnson, Christopher J ^c   Cronin, Kathleen A ^d   Ma, Jiemin ^a   Ryerson, A Blythe ^e   Mariotto, Angela ^d   Lake, Andrew J ^f   Wilson, Reda ^e   Sherman, Recinda L ^b   Anderson, Robert N ^g   Henley, S Jane ^e   Kohler, Betsy A ^b   Penberthy, Lynne ^d   Feuer, Eric J ^d   Weir, Hannah K ^e  

^a AMERICAN CANCER SOCIETY   (United States)

^b North American Association of Central Cancer Registries   (United States)

^c Cancer Data Registry of Idaho   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

^f INFORMATION MANAGEMENT SERVICES INC   (United States)

^g NATIONAL CENTER FOR HEALTH STATISTICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOID LEUKEMIA; ADOLESCENT; ADULT; AGED; ALASKA NATIVE; AMERICAN INDIAN; BILE DUCT CANCER; BLACK PERSON; BLADDER CANCER; BRAIN CANCER; BREAST CANCER; BRONCHUS CANCER; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER REGISTRY; CANCER STAGING; CANCER STATISTICS; CANCER SURVIVAL; CAUCASIAN; CHILD; CHILDHOOD CANCER; COLORECTAL CANCER; CONTROLLED STUDY; CUTANEOUS MELANOMA; ESOPHAGUS CANCER; ETHNIC DIFFERENCE; ETHNICITY; FEMALE; HUMAN; INFANT; KIDNEY CANCER; KIDNEY PELVIS CANCER; LARYNX CANCER; LEUKEMIA; LIVER CANCER; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASM; MORTALITY RATE; MOUTH CANCER; MYELOMA; NERVOUS SYSTEM TUMOR; NEWBORN; NONHODGKIN LYMPHOMA; OVARY CANCER; PANCREAS CANCER; PHARYNX CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RACE; RACE DIFFERENCE; REVIEW; RISK FACTOR; SEX RATIO; STANDARDIZED INCIDENCE RATIO; STANDARDIZED MORTALITY RATIO; STOMACH CANCER; SURVIVAL ANALYSIS; SURVIVAL RATE; SURVIVAL TIME; THYROID CANCER; TREND STUDY; UNITED STATES; UTERINE CERVIX CANCER; UTERUS CANCER; VERY ELDERLY; CROSS-SECTIONAL STUDY; ETHNOLOGY; INCIDENCE; MORTALITY; NEOPLASMS; NON PROFIT ORGANIZATION; PROPORTIONAL HAZARDS MODEL; PUBLIC HEALTH SERVICE; REGISTER; SEX DIFFERENCE;

AMERICAN CANCER SOCIETY; CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INCIDENCE; MALE; NEOPLASMS; PROPORTIONAL HAZARDS MODELS; REGISTRIES; SEER PROGRAM; SEX FACTORS; SURVIVAL RATE; UNITED STATES;

EID: 85017208283     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djx030     Document Type: Review

References (127)

1. Wingo PA, Ries LA, Rosenberg HM, et al. Cancer incidence and mortality, 1973-1995: A report card for the U.S. Cancer. 1998;82(6):1197-1207.
2. Wingo PA, Ries LA, Giovino GA, et al. Annual report to the nation on the status of cancer, 1973-1996, with a special section on lung cancer and tobacco smoking. J Natl Cancer Inst. 1999;91(8):675-690.
3. Ries LA, Wingo PA, Miller DS, et al. The annual report to the nation on the status of cancer, 1973-1997, with a special section on colorectal cancer. Cancer. 2000;88(10):2398-2424.
4. Howe HL, Wingo PA, Thun MJ, et al. Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J Natl Cancer Inst. 2001;93(11):824-842.
5. Edwards BK, Howe HL, Ries LA, et al. Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on U.S. cancer burden. Cancer. 2002;94(10):2766-2792.
6. Weir HK, Thun MJ, Hankey BF, et al. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst. 2003;95(17):1276-1299.
7. Jemal A, Clegg LX, Ward E, et al. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer. 2004; 101(1):3-27.
8. Edwards BK, Brown ML, Wingo PA, et al. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst. 2005;97(19):1407-1427.
9. Howe HL, Wu X, Ries LA, et al. Annual report to the nation on the status of cancer, 1975-2003, featuring cancer among U.S. Hispanic/Latino populations. Cancer. 2006;107(8):1711-1742.
10. Espey DK, Wu XC, Swan J, et al. Annual report to the nation on the status of cancer, 1975-2004, featuring cancer in American Indians and Alaska Natives. Cancer. 2007;110(10):2119-2152.
11. Jemal A, Thun MJ, Ries LA, et al. Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst. 2008;100(23):1672-1694.
12. Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010;116(3):544-573.
13. Kohler BA, Ward E, McCarthy BJ, et al. Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst. 2011;103(9):714-736.
14. Eheman C, Henley SJ, Ballard-Barbash R, et al. Annual report to the nation on the status of cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient physical activity. Cancer. 2012; 118(9):2338-2366.
15. Jemal A, Simard EP, Dorell C, et al. Annual report to the nation on the status of cancer, 1975-2009, featuring the burden and trends in human papillomavirus (HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst. 2013;105(3):175-201.
16. Edwards BK, Noone AM, Mariotto AB, et al. Annual report to the nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer. 2014;120(9):1290-1314.
17. Kohler BA, Sherman RL, Howlader N, et al. Annual report to the nation on the status of cancer, 1975-2011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state. J Natl Cancer Inst. 2015;107(6): djv048.
18. Ryerson AB, Eheman CR, Altekruse SF, et al. Annual report to the nation on the status of cancer, 1975-2012, featuring the increasing incidence of liver cancer. Cancer. 2016;122(9):1312-1337.
19. Measurement of progress against cancer. Extramural Committee to Assess Measures of Progress Against Cancer. J Natl Cancer Inst. 1990;82(10):825-835.
20. Dickman PW, Adami HO. Interpreting trends in cancer patient survival. J Intern Med. 2006;260(2):103-117.
21. Croswell JM, Ransohoff DF, Kramer BS. Principles of cancer screening: Lessons from history and study design issues. Semin Oncol. 2010;37(3): 202-215.
22. North American Association of Central Cancer Registries. NAACCR data quality criteria. Available at http://www.naaccr.org/Certification/Criteria. aspx. Accessed July 8, 2015.
23. World Health Organization. International Classification of Diseases for Oncology. 3rd ed. Geneva, Switzerland: World Health Organization Press; 2000.
24. Howlader N, Noone AM, Krapcho M, et al., eds. SEER Cancer Statistics Review, 1975-2012. Bethesda, MD: National Cancer Institute; 2015. http://seer.can cer.gov/csr/1975-2012/. Accessed June 10, 2016.
25. Young JL Jr, Roffers SD, Ries LAG, et al. SEER Summary Staging Manual 2000: Codes and Coding Instructions. Bethesda, MD: National Cancer Institute; 2001.
26. Clegg LX, Feuer EJ, Midthune DN, et al. Impact of reporting delay and reporting error on cancer incidence rates and trends. J Natl Cancer Inst. 2002;94(20): 1537-1545.
27. Kochanek KD, Murphy SL, Xu J, et al. Deaths: Final data for 2014. Natl Vital Stat Rep. 2016;65(4):1-122.
28. Espey DK, Jim MA, Richards TB, et al. Methods for improving the quality and completeness of mortality data for American Indians and Alaska Natives. Am J Public Health. 2014;104(suppl 3):S286-S294.
29. Espey DK, Wiggins CL, Jim MA, et al. Methods for improving cancer surveillance data in American Indian and Alaska Native populations. Cancer. 2008; 113(5 suppl):1120-1130.
30. Surveillance, Epidemiology, and End Results (SEER) Program, National Cancer Institute. Population estimates used in NCI's SEER∗Stat software. http://seer.cancer.gov/popdata/methods.html. Accessed July 13, 2015.
31. Centers for Disease Control and Prevention. National vital statistics system. https://www.cdc.gov/nchs/nvss/bridged-race/data-documentation.htm. Accessed December 22, 2016.
32. Ingram DD, Parker JD, Schenker N, et al. United States Census 2000 population with bridged race categories: Data evaluation and research. Vital Health Stat. 2003:2(135).
33. Weir HK, Johnson CJ, Mariotto AB, et al. Evaluation of North American Association of Central Cancer Registries' (NAACCR) data for use in population-based cancer survival studies. J Natl Cancer Inst Monogr. 2014; 2014(49):198-209.
34. Rosso S, De Angelis R, Ciccolallo L, et al. Multiple tumours in survival estimates. Eur J Cancer. 2009;45(6):1080-1094.
35. Surveillance Research Program, National Cancer Institute. SEER∗Stat software version 8.3.2. www.seer.cancer.gov/seerstat. Accessed June 10, 2016.
36. Tiwari RC, Clegg LX, Zou Z. Efficient interval estimation for age-adjusted cancer rates. Stat Methods Med Res. 2006;15(6):547-569.
37. National Cancer Institute. Joinpoint regression program, version 4.2.0.2. 2015. http://surveillance.cancer.gov/joinpoint/. Accessed July 14, 2015.
38. Kim HJ, Fay MP, Feuer EJ, et al. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000;19(3):335-351.
39. Clegg LX, Hankey BF, Tiwari R, et al. Estimating average annual per cent change in trend analysis. Stat Med. 2009;28(29):3670-3682.
40. National Cancer Institute. AAPC confidence intervals-Joinpoint Help System 4.3.1.0. https://surveillance.cancer.gov/help/joinpoint/settingparameters/advanced-tab/aapc-confidence-intervals. Accessed August 22, 2016.
41. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010.
42. US Department of Health and Human Services. The Health Consequences of Smoking: 50 Years of Progress. A Report of the Surgeon General. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2014. Printed with corrections, January 2014.
43. Jamal A, Homa DM, O'Connor E, et al. Current cigarette smoking among adults United States, 2005-2014. MMWR Morb Mortal Wkly Rep. 2015;64(44): 1233-1240.
44. Jacobs EJ, Newton CC, Carter BD, et al. What proportion of cancer deaths in the contemporary United States is attributable to cigarette smoking? Ann Epidemiol. 2015;25(3):179-182, e1.
45. Lortet-Tieulent J, Goding Sauer A, Siegel RL, et al. State-level cancer mortality attributable to cigarette smoking in the United States. JAMA Intern Med. 2016;176(12):1792-1798.
46. Siegel RL, Jacobs EJ, Newton CC, et al. Deaths due to cigarette smoking for 12 smoking-related cancers in the United States. JAMA Intern Med. 2015;175(9): 1574-1576.
47. Centers for Disease Control and Prevention. Best Practices for Comprehensive Tobacco Control Programs-2014. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2014.
48. Ward EM, Jemal A, Chen A. Increasing incidence of thyroid cancer: Is diagnostic scrutiny the sole explanation? Future Oncol. 2010;6(2):185-188.
49. Jemal A, Saraiya M, Patel P, et al. Recent trends in cutaneous melanoma incidence and death rates in the United States, 1992-2006. J Am Acad Dermatol. 2011;65(5 suppl 1):S17-S25, e1-e3.
50. Vaccarella S, Franceschi S, Bray F, et al. Worldwide thyroid-cancer epidemic? The increasing impact of overdiagnosis. N Engl J Med. 2016;375(7): 614-617.
51. Aschebrook-Kilfoy B, Grogan RH, Ward MH, et al. Follicular thyroid cancer incidence patterns in the United States, 1980-2009. Thyroid. 2013;23(8): 1015-1021.
52. Pellegriti G, Frasca F, Regalbuto C, et al. Worldwide increasing incidence of thyroid cancer: Update on epidemiology and risk factors. J Cancer Epidemiol. 2013;2013:965212.
53. Jemal A, Fedewa SA, Ma J, et al. Prostate cancer incidence and PSA testing patterns in relation to USPSTF screening recommendations. JAMA. 2015; 314(19):2054-2061.
54. Jemal A, Ma J, Siegel R, et al. Prostate cancer incidence rates 2 years after the US Preventive Services Task Force recommendations against screening. JAMA Oncol. 2016;2(12):1657-1660.
55. Prasad SM, Drazer MW, Huo D, et al. 2008 US Preventive Services Task Force recommendations and prostate cancer screening rates. JAMA. 2012;307(16): 1692-1694.
56. US Preventive Services Task Force. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2008;149(3):185-191.
57. World Cancer Research Fund American Institute for Cancer Research. Policy and Action for Cancer Prevention. Food, Nutrition, and Physical Activity: A Global Perspective. Washington, DC: AICR; 2009.
58. Ross JA, Spector LG. Cancers in children. In: D Schottenfeld, JF Fraumeni Jr, eds. Cancer Epidemiology and Prevention. 3rd ed. New York, NY: Oxford University Press; 2006:1251-1268.
59. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2013. Bethesda, MD: National Cancer Institute; 2016. http://seer.cancer.gov/csr/1975-2013/. Accessed July 7, 2016.
60. Barrington-Trimis JL, Cockburn M, Metayer C, et al. Trends in childhood leukemia incidence over two decades from 1992 to 2013. Int J Cancer. 2017; 140(5):1000-1008.
61. Ward E, DeSantis C, Robbins A, et al. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin. 2014;64(2):83-103.
62. Linet MS, Brown LM, Mbulaiteye SM, et al. International long-term trends and recent patterns in the incidence of leukemias and lymphomas among children and adolescents ages 0-19 years. Int J Cancer. 2016;138(8):1862-1874.
63. Cho H, Mariotto AB, Schwartz LM, et al. When do changes in cancer survival mean progress? The insight from population incidence and mortality. J Natl Cancer Inst Monogr. 2014;2014(49):187-197.
64. Loeb S, Bjurlin MA, Nicholson J, et al. Overdiagnosis and overtreatment of prostate cancer. Eur Urol. 2014;65(6):1046-1055.
65. Jani AB, Master VA, Rossi PJ, et al. Grade migration in prostate cancer: An analysis using the Surveillance, Epidemiology, and End Results registry. Prostate Cancer Prostatic Dis. 2007;10(4):347-351.
66. Hankey BF, Feuer EJ, Clegg LX, et al. Cancer surveillance series: Interpreting trends in prostate cancer-part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst. 1999;91(12):1017-1024.
67. Brawley OW. Trends in prostate cancer in the United States. J Natl Cancer Inst Monogr. 2012;2012(45):152-156.
68. Etzioni R, Gulati R, Tsodikov A, et al. The prostate cancer conundrum revisited: Treatment changes and prostate cancer mortality declines. Cancer. 2012;118(23):5955-5963.
69. Miller BA, Feuer EJ, Hankey BF. The increasing incidence of breast cancer since 1982: Relevance of early detection. Cancer Causes Control. 1991;2(2): 67-74.
70. Jemal A, Ward E, Thun MJ. Recent trends in breast cancer incidence rates by age and tumor characteristics among US women. Breast Cancer Res. 2007; 9(3):R28.
71. Chen L, Linden HM, Anderson BO, et al. Trends in 5-year survival rates among breast cancer patients by hormone receptor status and stage. Breast Cancer Res Treat. 2014;147(3):609-616.
72. Sledge GW, Mamounas EP, Hortobagyi GN, et al. Past, present, and future challenges in breast cancer treatment. J Clin Oncol. 2014;32(19):1979-1986.
73. Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353(17): 1784-1792.
74. Swan J, Breen N, Graubard BI, et al. Data and trends in cancer screening in the United States: Results from the 2005 National Health Interview Survey. Cancer. 2010;116(20):4872-4881.
75. Ciombor KK, Wu C, Goldberg RM. Recent therapeutic advances in the treatment of colorectal cancer. Annu Rev Med. 2015;66:83-95.
76. Salem ME, Hartley M, Unger K, et al. Neoadjuvant combined-modality therapy for locally advanced rectal cancer and its future direction. Oncology (Williston Park). 2016;30(6):546-562.
77. Hiatt RA, Klabunde C, Breen N, et al. Cancer screening practices from National Health Interview Surveys: Past, present, and future. J Natl Cancer Inst. 2002;94(24):1837-1846.
78. Finks JF, Osborne NH, Birkmeyer JD. Trends in hospital volume and operative mortality for high-risk surgery. N Engl J Med. 2011;364(22):2128-2137.
79. Hunter T. Treatment for chronic myelogenous leukemia: The long road to imatinib. J Clin Invest. 2007;117(8):2036-2043.
80. Dotan E, Aggarwal C, Smith MR. Impact of rituximab (rituxan) on the treatment of B-cell non-Hodgkin's lymphoma. P T. 2010;35(3):148-157.
81. DeVita VT Jr, Rosenberg SA. Two hundred years of cancer research. N Engl J Med. 2012;366(23):2207-2214.
82. DeVita VT, Schein PS. The use of drugs in combination for the treatment of cancer: Rationale and results. N Engl J Med. 1973;288(19):998-1006.
83. Armstrong GT, Chen Y, Yasui Y, et al. Reduction in late mortality among 5-year survivors of childhood cancer. N Engl J Med. 2016;374(9):833-842.
84. Children's Oncology Group. https://www.childrensoncologygroup.org/. Accessed January 4, 2017.
85. Pennock GK, Chow LQ. The evolving role of immune checkpoint inhibitors in cancer treatment. Oncologist. 2015;20(7):812-822.
86. Fedewa SA, Ward EM, Stewart AK, et al. Delays in adjuvant chemotherapy treatment among patients with breast cancer are more likely in African American and Hispanic populations: A national cohort study 2004-2006. J Clin Oncol. 2010;28(27):4135-4141.
87. Griggs JJ, Hawley ST, Graff JJ, et al. Factors associated with receipt of breast cancer adjuvant chemotherapy in a diverse population-based sample. J Clin Oncol. 2012;30(25):3058-3064.
88. Schmid M, Meyer CP, Reznor G, et al. Racial differences in the surgical care of Medicare beneficiaries with localized prostate cancer. JAMA Oncol. 2016; 2(1):85-93.
89. Wang EH, Yu JB, Abouassally R, et al. Disparities in treatment of patients with high-risk prostate cancer: Results from a population-based cohort. Urology. 2016;95:88-94.
90. Warner ET, Tamimi RM, Hughes ME, et al. Racial and ethnic differences in breast cancer survival: Mediating effect of tumor characteristics and sociodemographic and treatment factors. J Clin Oncol. 2015;33(20):2254-2261.
91. Hershman DL, Tsui J, Wright JD, et al. Household net worth, racial disparities, and hormonal therapy adherence among women with early-stage breast cancer. J Clin Oncol. 2015;33(9):1053-1059.
92. Freedman RA, Virgo KS, He Y, et al. The association of race/ethnicity, insurance status, and socioeconomic factors with breast cancer care. Cancer. 2011;117(1):180-189.
93. Shavers VL, Brown ML. Racial and ethnic disparities in the receipt of cancer treatment. J Natl Cancer Inst. 2002;94(5):334-357.
94. US Bureau of Labor Statistics. Labor force and characteristics by race and ethnicity, 2014. Report 1057. BLS Reports. 2015. https://www.bls.gov. Accessed August 10, 2016.
95. Pinheiro PS, Morris CR, Liu L, et al. The impact of follow-up type and missed deaths on population-based cancer survival studies for Hispanics and Asians. J Natl Cancer Inst Monogr. 2014;2014(49):210-217.
96. Johnson CJ, Weir HK, Yin D, et al. The impact of patient follow-up on population-based survival rates. J Registry Manag. 2010;37(3):86-103.
97. Warren JL, Klabunde CN, Schrag D, et al. Overview of the SEER-Medicare data: Content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40(8 suppl):IV-3-18.
98. Feuer EJ, Lee M, Mariotto AB, et al. The Cancer Survival Query System: Making survival estimates from the Surveillance, Epidemiology, and End Results program more timely and relevant for recently diagnosed patients. Cancer. 2012;118(22):5652-5662.
99. Feuer EJ, Rabin BA, Zou Z, et al. The Surveillance, Epidemiology, and End Results Cancer Survival Calculator SEER∗CSC: Validation in a managed care setting. J Natl Cancer Inst Monogr. 2014;2014(49):265-274.
100. Chen VW, Eheman CR, Johnson CJ, et al. Enhancing cancer registry data for comparative effectiveness research (CER) project: overview and methodology. J Registry Manag. 2014;41(3):103-112.
101. Liebler CA, Halpern-Manners A. A practical approach to using multiple-race response data: A bridging method for public-use microdata. Demography. 2008;45(1):143-155.
102. Arias E, Heron M, Hakes JK. The validity of race and Hispanic-origin reporting on death certificates in the United States: An update. National Center for Health Statistics. Vital Health Stat. 2016;2(172).
103. Pinheiro PS, Sherman RL, Trapido EJ, et al. Cancer incidence in first generation US Hispanics: Cubans, Mexicans, Puerto Ricans, and new Latinos. Cancer Epidemiol Biomarkers Prev. 2009;18(8):2162-2169.
104. Pinheiro PS, Sherman RL. Why an alternative algorithm for identification of Hispanic subgroups is useful. J Registry Manag. 2009;36(1):3-4.
105. Lowy D, Singer D, DePinho R, et al. Cancer moonshot countdown. Nat Biotechnol. 2016;34(6):596-599.
106. The Vice President's Cancer Moonshot. https://www.whitehouse.gov/can cermoonshot. Accessed August 19, 2016.
107. Fojo T, Grady C. How much is life worth: Cetuximab, non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst. 2009;101(15):1044-1048.
108. Kantarjian HM, Fojo T, Mathisen M, et al. Cancer drugs in the United States: Justum Pretium-the just price. J Clin Oncol. 2013;31(28):3600-3604.
109. Smith TJ, Hillner BE. Bending the cost curve in cancer care. N Engl J Med. 2011;364(21):2060-2065.
110. Zafar SY, Abernethy AP. Financial toxicity, Part I: A new name for a growing problem. Oncology (Williston Park). 2013;27(2):80-81, 149.
111. Ramsey S, Blough D, Kirchhoff A, et al. Washington State cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis. Health Aff (Millwood). 2013;32(6):1143-1152.
112. Ramsey SD, Bansal A, Fedorenko CR, et al. Financial insolvency as a risk factor for early mortality among patients with cancer. J Clin Oncol. 2016;34(9): 980-986.
113. Schnipper LE, Davidson NE, Wollins DS, et al. American Society of Clinical Oncology statement: A conceptual framework to assess the value of cancer treatment options. J Clin Oncol. 2015;33(23):2563-2577.
114. Aelion CM, Airhihenbuwa CO, Alemagno S, et al. The US Cancer Moonshot initiative. Lancet Oncol. 2016;17(5):e178-e180.
115. Neugut AI, Gross CP. Targeting the Cancer Moonshot. JAMA Oncol. 2016;2(4): 421-422.
116. Thun MJ, Jemal A. How much of the decrease in cancer death rates in the United States is attributable to reductions in tobacco smoking? Tob Control. 2006;15(5):345-347.
117. Jemal A, Ward E, Thun M. Declining death rates reflect progress against cancer. PLoS One. 2010;5(3):e9584.
118. Jemal A, Thun M, Yu XQ, et al. Changes in smoking prevalence among US adults by state and region: Estimates fromthe Tobacco Use Supplement to the Current Population Survey, 1992-2007. BMC Public Health. 2011;11: 512.
119. Holmes CB, King BA, Babb SD. Stuck in neutral: Stalled progress in statewide comprehensive smoke-free laws and cigarette excise taxes, United States, 2000-2014. Prev Chronic Dis. 2016;13:E80.
120. American Cancer Society Cancer Action Network. How do you measure up? A progress report on state legislative activity to reduce cancer incidence and mortality. 14th ed. American Cancer Society Cancer Action Network. 2016. http://www.acscan.org/content/report-cards/2016/. Accessed August 22, 2016.
121. Fedewa SA, Sauer AG, Siegel RL, et al. Prevalence of major risk factors and use of screening tests for cancer in the United States. Cancer Epidemiol Biomarkers Prev. 2015;24(4):637-652.
122. Doria-Rose VP, White MC, Klabunde CN, et al. Use of lung cancer screening tests in the United States: Results from the 2010 National Health Interview Survey. Cancer Epidemiol Biomarkers Prev. 2012;21(7): 1049-1059.
123. Reagan-Steiner S, Yankey D, Jeyarajah J, et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years-United States, 2014. MMWR Morb Mortal Wkly Rep. 2015;64(29): 784-792.
124. Jemal A, Fedewa SA. Prevalence of hepatitis C virus testing in cohorts born between 1945 and 1965 in the US Am J Prev Med. 2015;48(5):e7-e9.
125. Ogden CL, Carroll MD, Lawman HG, et al. Trends in obesity prevalence among children and adolescents in the United States, 1988-1994 through 2013-2014. JAMA. 2016;315(21):2292-2299.
126. Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med. 2003;348(17):1625-1638.
127. Cogliano VJ, Baan R, Straif K, et al. Preventable exposures associated with human cancers. J Natl Cancer Inst. 2011;103(24):1827-1839.